Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Cash from Financing Activities data on record, last reported at $348000.0 in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 2220.0% year-over-year to $348000.0; the TTM value through Sep 2025 reached $1.3 million, down 98.92%, while the annual FY2024 figure was $98.9 million, 259.71% up from the prior year.
  • Cash from Financing Activities reached $348000.0 in Q3 2025 per GLUE's latest filing, down from $365000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $98.0 million in Q2 2024 and bottomed at $14000.0 in Q1 2025.
  • Average Cash from Financing Activities over 3 years is $11.6 million, with a median of $365000.0 recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: soared 8068.58% in 2024, then tumbled 99.63% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $25.2 million in 2023, then crashed by 97.58% to $608000.0 in 2024, then crashed by 42.76% to $348000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $348000.0 in Q3 2025, $365000.0 in Q2 2025, and $14000.0 in Q1 2025.